View Post

Greenwich LifeSciences Presents Immune Response Phase IIb Poster

In Clinical Studies News by Barbara Jacoby

From: businesswire.com Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a …

View Post

Treatment and outlook for stage 2 breast cancer

In In The News by Barbara Jacoby

Source: healthline.com From: medicalnewstoday.com People with stage 2 breast cancer have cancer cells in their breast tissue, nearby lymph nodes, or both. Stage 2 breast cancer is an early stage of breast cancer in which the cancer has not spread beyond the breast tissue or surrounding lymph nodes. Cancer stages describe the extent to which the cancer has spread and …

View Post

Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: businesswire.com Immunopheresis™ therapy holds great promise for avoiding serious drawbacks of existing pharmaceuticals and improving patients’ quality of life Immunicom, Inc., a global biotechnology company pioneering novel “subtractive” immunotherapies, today announced that the Immunopheresis™ LW-02 blood-filtering column, its leading immuno-oncology product with FDA Breakthrough Device status, has received regulatory clearance (CE Mark certification) in Europe for use in adults …

View Post

Trodelvy: Magic bullet for triple-negative breast cancer

In In The News by Barbara Jacoby

By: Ivanhoe Newswire From: winknews.com About 15 percent of all women diagnosed with breast cancer have triple-negative breast cancer, meaning drugs that target estrogen, progesterone, and HER-2 protein—won’t work. In the past, if the cancer returned, patients have had very few options. More on a newly approved drug that is stopping the cancer in its tracks. Jane Ellen Keenan is …

View Post

Surgery Boosts Survival in De Novo Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Locoregional treatment was found to improve survival for patients with de novo stage IV breast cancer and bone-only metastasis, according to the results of a multicenter registry study reported at the 17th St. Gallen International Breast Cancer Conference 2021. BOMET MF14-01 (ClinicalTrials.gov Identifier: NCT02125630) included 505 patients with de novo stage IV breast cancer …

View Post

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …

View Post

Better Record “Integration” Would Boost Links Between Oncologists, Primary Care

In In The News by Barbara Jacoby

By: Mary Caffrey From: ajmc.com A panel at the NCCN Virtual Annual Meeting finds that while primary care physicians and oncologists can share information, records may not be well integrated and in easy-to-use formats. When connections among oncologists, cancer patients, and primary care physicians are finely tuned, the results can be life-saving for patients like Felicia Harris, a 14-year breast …

View Post

Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …

View Post

Predicting future breast cancer with precision

In In The News by Barbara Jacoby

By: Alex Lathbridge From: cancerresearchuk.org Ductal carcinoma in situ (or DCIS) is a condition where some of the cells lining the ducts of the breast tissue have started to turn into cancer cells. It’s an example of something known as a pre-invasive cancer – the abnormal cells are all contained inside the lining of the ducts, but have the potential …

View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …